// In this new study, funded by GW Research and the National Institute for Health Research (NIHR) Biomedical Research Centre, 88 patients with psychosis received either CBD or placebo for six weeks, alongside their existing #antipsychotic #medication
. Before and after treatment, researchers assessed their level of symptoms, functioning, and cognitive performance, while the patient’s psychiatrist rated their condition overall. 🌿🌿🌿
Patients treated with #CBD
had lower levels of psychotic symptoms than those who received a placebo, and were more likely to have been rated as ‘improved’ by their psychiatrist. There were also trends for improvements in cognitive performance and in their level of functioning. Treatment with CBD was not associated with significant side effects. 🌿🌿🌿
Professor Philip McGuire, the lead author, from King’s College London’s Institute of #Psychiatry
(IoPPN), said: ‘Conventional antipsychotic drugs act by blocking #dopamine
receptors. However, dopamine is not the only #neurotransmitter
whose function is altered in psychosis, and in some patients dopamine function may be relatively normal.